Corvus Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
CRVS$11.35+7.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | CORVUS PHARMACEUTICALS, INC. | |
|---|---|---|
| | | |
| Date: March 19, 2024 | By: | /s/ RICHARD. A. MILLER |
| | | Richard A. Miller, M.D. |
| | | President, Chief Executive Officer and Director |
| | | (Principal Executive Officer) |
| | | |
| Date: March 19, 2024 | By: | /s/ LEIV LEA |
| | | Leiv Lea |
| | | Chief Financial Officer |
| | | (Principal Financial and Accounting Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.